INmune Bio reports primary endpoint of MINDFuL study not met

In a corporate presentation for June, INmune Bio (INMB) stated that the “primary endpoint was not met” in the MINDFuL study, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in participants with early Alzheimer’s disease. The study results included “consistent absolute effect sizes indicative of positive effects attributable to treatment with XPro” and the “safety outcomes indicated good safety and tolerability profile in participants with Early AD,” the slides added.